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Abstract
Background: Post-resuscitation hemodynamic instability following out-of-hospital cardiac arrest (OHCA) may occur
from myocardial dysfunction underlying cardiogenic shock and/or inflammation-mediated distributive shock.
Distinguishing the predominant shock subtype with widely available clinical metrics may have prognostic and
therapeutic value.
Methods: A two-hospital cohort was assembled of patients in shock following OHCA. Left ventricular ejection
fraction (LVEF) was assessed via echocardiography or cardiac ventriculography within 1 day post arrest and
used to delineate shock physiology. The study evaluated whether higher LVEF, indicating distributive-predominant
shock physiology, was associated with neurocognitive outcome (primary endpoint), survival, and duration of multiple
organ failures. The study also investigated whether volume resuscitation exhibited a subtype-specific association with
outcome.
Results: Of 162 patients with post-resuscitation shock, 48% had normal LVEF (> 40%), consistent with distributive shock
physiology. Higher LVEF was associated with less favorable neurocognitive outcome (OR 0.74, 95% CI 0.58–0.94 per
10% increase in LVEF; p = 0.01). Higher LVEF also was associated with worse survival (OR 0.81, 95% CI 0.67–0.97;
p = 0.02) and fewer organ failure-free days (β = – 0.67, 95% CI – 1.28 to − 0.06; p = 0.03). Only 51% of patients received
a volume challenge of at least 30 ml/kg body weight in the first 6 h post arrest, and the volume received did not differ
by LVEF. Greater volume resuscitation in the first 6 h post arrest was associated with favorable neurocognitive outcome
(OR 1.59, 95% CI 0.99–2.55 per liter; p = 0.03) and survival (OR 1.44, 95% CI 1.02–2.04; p = 0.02) among patients with
normal LVEF but not low LVEF.
Conclusions: In post-resuscitation shock, higher LVEF—indicating distributive shock physiology—was associated with
less favorable neurocognitive outcome, fewer days without organ failure, and higher mortality. Greater early volume
resuscitation was associated with more favorable neurocognitive outcome and survival in patients with this shock
subtype. Additional studies with repeated measures of complementary hemodynamic parameters are warranted to
validate the clinical utility for subtyping post-resuscitation shock.
Keywords: Cardiac arrest, Shock, Cardiogenic shock, Distributive shock, Reperfusion injury, Systemic inflammatory
response syndrome
* Correspondence: jrb2266@cumc.columbia.edu
6Center for Acute Respiratory Failure, Division of Pulmonary, Allergy, and
Critical Care Medicine, Columbia University College of Physicians & Surgeons,
622 W. 168th Street, 8E101, New York, NY 10032, USA
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Anderson et al. Critical Care  (2018) 22:162 
https://doi.org/10.1186/s13054-018-2078-x
Background
Post-resuscitation circulatory shock occurs in most pa-
tients admitted after out-of-hospital cardiac arrest
(OHCA) and is a primary contributor to subsequent
mortality [1–3]. Optimal hemodynamic management of
post-resuscitation shock is complicated by the myriad
pathophysiological processes involved—which together
are termed post-cardiac arrest syndrome (PCAS) [4–7].
Post-resuscitation global myocardial stunning can
cause transient pump failure lasting several hours [1, 8–
10], and is thought to result from a combination of oxi-
dative stress, microthrombi formation, adrenergic excess,
cytokine release, and myocardial ischemia–reperfusion
injury [7, 11–13]. When present, chronic systolic heart
failure and acute coronary syndrome also may contrib-
ute to post-arrest cardiogenic shock [14, 15].
At the same time, global ischemia–reperfusion injury
may precipitate systemic vasodilation. Associated systemic
inflammatory response, endothelial injury, capillary leak,
impaired vasoregulation, end-organ microvascular
thrombi, and adrenal suppression share many similar-
ities with septic shock [7, 16]. Concomitant infection
also appears to be common and may contribute fur-
ther to distributive shock [17].
Distinguishing the relative contributions of pump fail-
ure (cardiogenic shock) and vasodilation (distributive
shock) from post-resuscitation shock may have import-
ant implications for personalizing hemodynamic man-
agement, particularly if done readily at the bedside.
Therefore, the present study investigated whether early
assessment of left ventricular ejection fraction (LVEF)
could identify subtypes of shock that have potential
prognostic and therapeutic relevance, including specific-
ally whether the association between early intravascular
volume resuscitation and clinical outcome differed by
shock subtype.
Methods
This study was approved by the hospitals’ institu-
tional review boards with waiver of consent. See
Additional file 1 for further details on methods.
Study population
A two-hospital retrospective cohort was assembled using
a previously validated approach for identifying OHCA
admissions [18, 19]. Pertinent medical records between
2008 and 2014 were screened using relevant billing
codes [18] and reviewed manually by physician investi-
gators to confirm eligibility. Included were adults aged
≥18 years in shock following nontraumatic OHCA who
required advanced life support (vasopressors and/or
mechanical ventilation) for at least the first 6 h of admis-
sion but survived over that time. Shock was defined as
systolic blood pressure ≤ 90 mmHg or vasopressor
administration, criteria adopted from the Brussels Con-
ference on Clinical Trials for the Treatment of Sepsis
[20] and used elsewhere in prominent ICU clinical trials
networks [21]. Patients who met this definition of shock
at any time within the first 24 h of ICU admission were
considered to have shock on day 1. LVEF assessment
within 1 day post arrest was required for inclusion in the
main study cohort to reflect early pathophysiology in light
of post-arrest myocardial dysfunction that may evolve over
successive days [1]. Exclusions are defined in Fig. 1.
A second, expanded cohort was created for sensitivity
analyses, detailed in the following, by including patients
meeting all eligibility criteria irrespective of whether
LVEF was assessed within 1 day post arrest. In this ex-
panded sensitivity cohort, LVEF assessment was consid-
ered at any time during admission; patients without
LVEF assessment during admission were assumed to
have normal LVEF. Such handling of LVEF in the ex-
panded sensitivity cohort was based on the following
reasoning: if LVEF was depressed later during the
hospitalization, it likely also was depressed at ICU ad-
mission; and pretest probability guides the use of echo-
cardiography and ventriculography, such that if
clinicians had little suspicion for depressed LVEF clinic-
ally, then LVEF was less likely to be measured.
Left ventricular ejection fraction
LVEF was ascertained from either echocardiogram or
left ventriculogram reports, whichever was performed
on the earliest hospital day post arrest. If LVEF was re-
ported from both methods on the same calendar day,
the value from the left ventriculogram was used. LVEF >
40% was considered normal for this study, based on
international consensus guidelines that define systolic
heart failure below this threshold [22, 23].
Primary outcome
The primary outcome, specified a priori for consistency
with existing literature [24–28], was favorable neurocog-
nitive outcome at hospital discharge, defined as Cerebral
Performance Category (CPC) 1 or 2 (see Additional file 1)
[29, 30]. CPC was determined independently by two study
physicians blinded to LVEF, hemodynamic/resuscitation
data, and other baseline illness severity measures as de-
scribed previously [19], with discordant ratings resolved
by consensus.
Secondary outcomes
Secondary outcomes included shock-free days,
ventilator-free days, renal, hepatic, and coagulation
failure-free days, as well as days free from any of the
aforementioned organ failures through day 28 (see
Additional file 1). ICU-free days and hospital-free
days were also evaluated.
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Statistics
For all analyses, a two-sided α threshold of 0.05 was
used for statistical significance.
Main analyses of clinical outcomes
LVEF was entered as a continuous variable for all main
analyses. This approach was chosen, rather than dichot-
omizing LVEF, to allow for potential differences in prog-
nostic relevance within the range of systolic heart failure
[31]. Odds ratios and model effect estimates are reported
per increase of 10% in LVEF (e.g., from 30% to 40%). In
the prespecified statistical plan, the main analyses of all
clinical endpoints were adjusted for APACHE II score to
account for differences in illness severity on admission.
Linearity between LVEF and the primary outcome on
the log-scale was assessed by inserting higher-order
quadratic and cubic terms for LVEF in the model and
testing for statistical significance, and by recoding LVEF
as a log-transformed variable and comparing model
fit (c-statistic) to the model with nontransformed
LVEF. For graphical presentation, analysis of the main
outcome was repeated using a Cox model and plotted
as the APACHE II score-adjusted cumulative inci-
dence for discharge with favorable neurocognitive out-
come according to normal vs low LVEF. The
proportional hazards assumption was confirmed via a
second Cox model that included an interaction term
for LVEF with time; a nonsignificant interaction coef-
ficient supported proportionality.
Sensitivity analyses for primary outcome
Multiple sensitivity analyses were performed for the
primary outcome, favorable neurocognitive outcome, to
ensure findings were not dependent on the method of
covariate adjustment or handling of the main predictor
or outcome variables (see Additional file 1).
Subgroup analysis by initial rhythm
Initial arrest rhythm was not included as a covariate due
to concern that the shock subtype may be downstream
of the causal pathway and hence partially mediate the ef-
fect of the arrest rhythm. Thus, to ensure that LVEF was
not simply a marker of the initial arrest rhythm, sub-
group analyses were performed separately for patients
with shockable and nonshockable rhythm, adjusting for
APACHE II score. To address limited statistical power
from small subgroup sizes, these analyses were repeated
using the aforementioned expanded sensitivity cohort
with dichotomized LVEF.
Post-hoc analysis for residual confounding
To ensure LVEF was not simply a marker of early differ-
ences in hemodynamic stability, additional models were
developed evaluating whether LVEF predicted mean ar-
terial pressure or vasopressor dose (norepinephrine
equivalent) either at baseline or as a time-weighted aver-
age over the first 48 h. The association between LVEF
and therapeutic hypothermia also was evaluated, owing
to concern for possible collinearity between LVEF and
Fig. 1 Study flow diagram. OHCA out-of-hospital cardiac arrest, ICU intensive care unit, LVEF left ventricular ejection fraction
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arrest rhythm, since hypothermia is most often applied
for patients with shockable rhythm.
Volume resuscitation and clinical outcomes
To evaluate the subtype-specific association of volume
resuscitation at 6 and 24 h with favorable neurocognitive
outcome and survival, separate logistic models were con-
structed for patients with normal and low LVEF, adjust-
ing for APACHE II score, baseline vasopressor dose
(norepinephrine equivalent), and arrest rhythm, covari-
ates selected a priori for clinical relevance.
Results
Characteristics of study population
One hundred and sixty-two patients met the eligibility
criteria (Fig. 1) and were included in all analyses. LVEF
was assessed via echocardiogram in 154 patients and by
left ventriculogram in eight patients. An additional 73
patients met all eligibility criteria except for an LVEF
assessment within 1 calendar day of arrest and were
included only in the sensitivity analyses as noted; their
baseline characteristics were comparable to those with
normal LVEF (> 40%) (Table 1).
Eighty-three percent of included patients (135 of 162)
meeting the shock criteria received continuous vasopres-
sor and/or inotrope infusion at ICU admission, and 90%
received continuous vasopressor/inotrope infusion
within the first 48 h. Among patients meeting the shock
criteria who were hypotensive but did not receive con-
tinuous vasopressor/inotrope infusion, initial lactate was
on average 2.9 mmol/L and a median of 2 (interquartile
range 1–3) nonshock organ failures were present on
admission, indicative of end-organ dysfunction in the
setting of hypotension.
Half (48%) of the included shock patients had a normal
LVEF (> 40%) within 1 day after arrest. Pre-arrest LVEF
was available in 54 patients, in whom it was highly corre-
lated with the post-arrest measure (ρ = 0.69; p < 0.01) but
on average slightly higher than that post arrest (pre-arrest
vs post-arrest difference in LVEF 7 ± 16%; p < 0.01).
Patients in shock despite normal LVEF had lower peak
troponin, were less likely to be diagnosed with
ST-elevation myocardial infarction, and were less likely
to undergo coronary angiography, coronary stenting, or
receive an intraaortic balloon pump (Table 1).
While 43% of included patients survived to hospital
discharge, only 22% had a favorable neurocognitive out-
come at discharge. Additional patient characteristics are
presented in Table 1.
LVEF and neurocognitive outcome
In unadjusted analysis, higher LVEF was associated with
less favorable neurocognitive outcome (OR for favorable
neurocognitive outcome 0.82, 95% CI 0.67–1.00 per 10%
increase in LVEF; p = 0.048) (Fig. 2).
In the prespecified primary analysis, higher LVEF
remained associated with less favorable neurocognitive
outcome after adjusting for APACHE II score (OR 0.74,
95% CI 0.58–0.94 per 10% increase in LVEF; p = 0.01).
Sensitivity analyses confirmed that the association
between higher LVEF and less favorable neurocognitive
outcome did not depend on the method of quantifying
illness severity, the included covariates, or handling of
the dependent and independent variables (Fig. 2;
Additional file 1: Table S2). The linearity assumption of
LVEF with favorable neurocognitive outcome on the
log-odds scale held up on testing for the range of values
in our dataset. The Cox APACHE II score-adjusted
cumulative incidence for discharge with favorable neuro-
cognitive outcome according to normal vs low LVEF is
shown in Fig. 3; the Cox model proportionality assump-
tion was tested and deemed valid.
In the expanded sensitivity cohort (n = 235), normal
LVEF again was associated with less favorable neurocog-
nitive outcome compared to low LVEF in unadjusted
analysis (OR 0.48, 95% CI 0.25–0.90 for normal vs low
LVEF; p = 0.02) and APACHE II score-adjusted analysis
(OR 0.33, 95% CI 0.16–0.67; p < 0.01).
LVEF and survival
In unadjusted analysis, higher LVEF was not signifi-
cantly associated with survival to discharge (OR 0.87,
95% CI 0.73–1.02 per 10% increase in LVEF; p = 0.09).
However, after adjusting for baseline illness severity
via the APACHE II score, higher LVEF was signifi-
cantly associated with less survival (OR for survival
0.81, 95% CI 0.67–0.97 per 10% increase in LVEF;
p = 0.02). This association remained significant after
adding therapeutic hypothermia to the APACHE II
score-adjusted model (Fig. 2).
LVEF and other secondary outcomes
Higher LVEF was associated with fewer days free from
shock, mechanical ventilation, renal failure, coagulation
failure, and any organ failure in APACHE II
score-adjusted analyses (Fig. 4). LVEF was not associated
with hepatic failure-free days. Higher LVEF also was asso-
ciated with fewer ICU-free days and fewer hospital-free
days in APACHE II score-adjusted analyses (Fig. 4).
Subgroup analysis by initial rhythm
Among patients with an arrest rhythm of ventricular
tachycardia or ventricular fibrillation (n = 86), the odds
ratio for neurocognitive outcome favored lower LVEF, but
this association did not reach statistical significance (OR
0.76, 95% CI 0.54–1.07; p = 0.10). Among patients with a
nonshockable rhythm (n = 76), there was no suggestion of
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Table 1 Baseline characteristics for patients in shock according to LVEF assessed within 1 day after arrest
Patient characteristic LVEF > 40% (n = 78) LVEF ≤ 40% (n = 84) p value Initial LVEF unknowna (n = 73)
Age (years) 63 ± 15 64 ± 15 0.73 64 ± 20
Female 26 (33%) 20 (24%) 0.22 27 (37%)
Prior medical history
Coronary disease 18 (23%) 34 (40%) 0.02 18 (25%)b
Congestive heart failure 12 (15%) 34 (40%) < 0.01 17 (23%)b
Chronic pulmonary disease 12 (15%) 11 (13%) 0.82 17 (23%)
Arrest characteristics
Witnessed arrest 56 (72%) 68 (81%) 0.20 48 (66%)b
Bystander CPR 41 (53%) 50 (60%) 0.43 37 (51%)
Time from collapse to CPR initiation (min) 2 (1–7) 2 (0–6) 0.97 2 (0–5)
Duration of CPR before sustained ROSC (min) 15 (10–38) 18 (9–30) 0.65 20 (11.5–42)
Initial rhythm VT/ VF 25 (32%) 61 (73%) < 0.01 22 (30%)b,c
Comatose after ROSC 72 (92%) 80 (95%) 0.52 68 (93%)
Therapeutic hypothermia after ROSC 59 (76%) 75 (89%) 0.02 51 (70%)b,c
Markers of cardiac injury
Peak troponin in first 24 h (ng/ml) 0.3 (0.1–1.0) 0.9 (0.3–2.7) < 0.01 0.3 (0.1–0.9)b,c
ST-elevation myocardial infarction 8 (10%) 23 (27%) .01 6 (8%)b,c
Coronary angiography during hospitalization 18 (23%) 45 (54%) < 0.01 13 (18%)c
Coronary stent placed during hospitalization 7 (9%) 20 (24%) 0.01 6 (8%)b
Intraaortic balloon pump during hospitalization 3 (4%) 14 (17%) < 0.01 6 (8%)
LVEF (%) within ≤ 1 day after arrest 59 ± 10 26 ± 9 < 0.01 N/A
Markers of systemic illness severity
APACHE II score 35 ± 6 36 ± 6 0.09 35 ± 7
SOFA on day 1 12 ± 3 12 ± 3 0.67 12 ± 3
Number of organ failures on day 1d 3 ± 1 3 ± 1 0.97 3 ± 1
Initial vasopressor dose, norepinephrine equivalent (μg/min) 7.5 (2.5–20.1) 10.1 (2.6–21.5) 0.45 10.4 (3.5–21.7)
Initial lactate (mmol/L) 5.8 ± 4.7 4.1 ± 2.8 0.01 6.6 ± 5.2b,c
Peak lactate in first 24 h (mmol/L) 5.9 ± 4.7 4.6 ± 3.1 0.04 7.6 ± 6.1b,c
Initial respiratory characteristics
Tidal volume (ml/kg PBW) 8.0 ± 1.9 8.1 ± 1.8 0.79 8.0 ± 1.3
PEEP (cmH2O) 5 (5–8) 5 (5–10) 0.14 5 (5–5)
b,c
Peak inspiratory pressure (cmH2O) 27 ± 8 26 ± 8 0.75 27 ± 9
FiO2 100 (80–100) 100 (60–100) 0.40 100 (60–100)
pH 7.22 ± 0.19 7.23 ± 0.15 0.53 7.18 ± 0.20
PaCO2 (mmHg) 44 (39–62) 47 (37–56) 0.66 45 (37–57.5)
PaO2 (mmHg) 212 ± 128 202 ± 130 0.62 229 ± 167
PaO2:FiO2 237 ± 141 237 ± 148 0.99 258 ± 174
Volume resuscitation in first 6 h (L) 2.9 ± 1.8 2.7 ± 1.7 0.50 2.9 ± 2.0
Volume challenge ≥ 30 ml/kg in first 6 h 42 (54%) 41 (49%) 0.53 37 (51%)
Volume resuscitation in first 24 h (L) 6.1 ± 3.5 5.6 ± 3.1 0.34 6.0 ± 3.0
Descriptive statistics shown as mean ± standard deviation, median (interquartile range), or number (%) and compared with t, Wilcoxon rank-sum, or chi-square tests
as appropriate
LVEF left ventricular ejection fraction, CPR cardiopulmonary resuscitation, ROSC return of spontaneous circulation, VT ventricular tachycardia, VF ventricular
fibrillation, N/A not applicable, APACHE II Acute Physiology and Chronic Health Evaluation II, SOFA sequential organ failure assessment score, PBW predicted body
weight, PEEP positive end-expiratory pressure, FiO2 fraction of inspired oxygen, PaCO2 partial pressure of carbon dioxide in arterial blood, PaO2 partial pressure of
oxygen in arterial blood
aLVEF not assessed within ≤ 1 day post arrest, including 42 patients in whom LVEF was never assessed during admission and 31 patients in whom assessment
occurred > 1 day after arrest
bp < 0.05 compared to patients with LVEF ≤ 40%. No values differed significantly compared to patients with LVEF > 40%
cp < 0.05 compared to all included patients with LVEF assessment within ≤ 1 day post arrest
dCardiovascular failure defined as systolic blood pressure ≤ 90 mmHg or any vasopressor use. Respiratory failure defined by invasive mechanical ventilation.
Coagulation, renal, and hepatic organ failures defined according to Brussels multiple organ dysfunction criteria
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association between LVEF and favorable neurocognitive
outcome (OR 0.94, 95% CI 0.59–1.50; p = 0.81).
In the expanded sensitivity cohort, normal LVEF was
associated with less favorable neurocognitive outcome
among patients with ventricular tachycardia or ventricu-
lar fibrillation (n = 108; OR 0.34, 95% CI 0.12–0.93; p =
0.03) and was not associated with neurocognitive out-
come among patients with nonshockable rhythm (n =
127; OR 1.01, 95% CI 0.19–5.22; p = 1.00).
Volume resuscitation and clinical outcomes
Intravascular volume resuscitation did not differ for pa-
tients with normal vs low LVEF during the first 6 h (2.9
± 1.8 vs 2.7 ± 1.7 l; p = 0.504) nor through 24 h (6.1 ± 3.5
vs 5.6 ± 3.1 l; p = 0.34) after arrest. Only half of all shock
patients (51%) received a volume challenge of at least
30 ml/kg body weight in the first 6 h post arrest.
Among patients with normal LVEF, greater intra-
vascular volume resuscitation during the first 6 h
post arrest was associated with favorable neurocogni-
tive outcome (OR 1.59, 95% CI 0.99–2.55 per liter of
volume; p = 0.03) and survival (OR 1.44, 95% CI
1.02–2.04; p = 0.02) in models adjusting for APACHE
II score, baseline vasopressor dose, and arrest
rhythm. By contrast, among patients with low LVEF,
no association was found between 6-h volume resus-
citation and either neurocognitive outcome or
Fig. 2 LVEF and patient outcomes after OHCA. Sensitivity analyses performed for favorable neurocognitive outcome (CPC 1–2, primary study
outcome) and survival at hospital discharge, to confirm results were not dependent on covariate adjustment. ORs indicate odds of favorable vs
unfavorable outcome per 10% increase in LVEF. Additional sensitivity analyses (see Additional file 1) confirmed results did not depend on method
of quantifying illness severity nor handling of dependent and independent variables. *Prespecified primary analysis of main outcome. CI confidence
interval, LVEF left ventricular ejection fraction, APACHE II Acute Physiological and Chronic Health Evaluation II, TH therapeutic hypothermia
Fig. 3 Adjusted probability of discharge with favorable neurocognitive outcome over time. Calculated from Cox proportional hazards model adjusting
for APACHE II score. Hazard ratio for normal LVEF compared to low LVEF 0.46, 95% CI 0.23–0.91; p = 0.03. LVEF left ventricular ejection fraction
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survival. Total 24-h volume resuscitation was not
associated with neurocognitive outcome or survival
irrespective of LVEF.
Analyses for residual confounding
LVEF was associated with neither mean arterial pressure
nor vasopressor dose, regardless of whether baseline or
48-h time-weighted average value was considered (see
Additional file 1). Higher LVEF was associated with less
use of therapeutic hypothermia (OR 0.80, 95% CI 0.64–
1.00; p = 0.047), likely owing to differences in incidence
of initial shockable rhythm among normal vs low LVEF
patients (32% vs 73%, respectively; p < 0.01). However,
adding therapeutic hypothermia to the models did not
change the significant association between higher LVEF
and less favorable clinical outcomes, and therapeutic
hypothermia was not associated with favorable neuro-
cognitive outcome or survival in this cohort.
Discussion
PCAS is a state of acute end-organ injury stemming
from intra-arrest global tissue hypoxia and subsequent
ischemia–reperfusion injury, exacerbated by post-arrest
hemodynamic instability, inflammation, and persistent
effects of the underlying precipitant of arrest [7]. Clinical
experience and existing literature indicate substantial
physiological and biological heterogeneity among PCAS
patients following OHCA [32, 33]. Recognition of clinic-
ally discernible phenotypes therefore may provide both
prognostic and potential therapeutic value.
This study supports considering at least two subtypes
of circulatory shock in PCAS: cardiogenic-predominant
shock and distributive-predominant (noncardiogenic)
shock. In this study, the more shock reflected distribu-
tive rather than cardiogenic physiology, the worse the
patient’s outcome. Among patients in post-resuscitation
shock after OHCA, higher LVEF was associated with
worse neurocognitive outcome. This conclusion held
through several sensitivity analyses scrutinizing covariate
adjustment and handling of the independent and
dependent variables of interest. Higher LVEF also was
associated with prolonged duration of shock and organ
failures and greater risk of death among patients in
post-resuscitation shock.
In addition to prognostic value, this study also sug-
gests that subtyping PCAS shock could have potential
relevance to personalizing treatment strategies. For in-
stance, a patient with cardiogenic shock typically would
not receive early aggressive intravascular volume resusci-
tation, which by contrast is standard of care for
inflammation-mediated distributive shock, such as in
sepsis [34–37].
In our cohort, only half (51%) of the patients received
a volume challenge ≥ 30 ml/kg in the first 6 h post ar-
rest, and cumulative volume resuscitation during this
period did not differ by shock subtype. Intravascular vol-
ume resuscitation exhibited a subtype-specific associ-
ation with clinical outcomes: more volume resuscitation
during the first 6 h post arrest was associated with better
neurocognitive outcome and survival among patients in
shock with normal LVEF, but no such association was
found among patients in shock with low LVEF. Volume
received through 24 h was not predictive of outcome in
either subtype. Thus, as with sepsis, these data suggest—
but do not prove—that volume resuscitation may be
most effective early in the course of proinflammatory
distributive shock.
Several possibilities may explain the observed link be-
tween distributive-predominant shock physiology and
worse outcome. The natural history of cardiogenic shock
may be more favorable in the subset of patients in whom
myocardial stunning is the primary contributor because
Fig. 4 LVEF and secondary outcomes. Effect estimates with 95% CIs for outcome per 10% increase in LVEF from linear regression models adjusting for
APACHE II score. CI confidence interval, LVEF left ventricular ejection fraction, APACHE II Acute Physiological and Chronic Health Evaluation II,
ICU intensive care unit
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severe cardiac dysfunction can be transient in these pa-
tients [1, 10]. Supporting this possibility, lower LVEF
was associated with more shock-free days in our cohort.
In contrast, with distributive shock, systemic inflamma-
tion may be propagated for days by the immune re-
sponse to damage-associated and pathogen-associated
molecular patterns, contributing to ongoing end-organ
injury long after return of spontaneous circulation [16].
This underlying biology may explain the association of
higher LVEF with longer duration of multiple organ fail-
ures and worse neurocognitive outcome in this cohort.
Low LVEF is a known risk factor for arrest due to
ventricular arrhythmia, which typically is associated with
better prognosis [38]. Thus, it is possible that the associ-
ation between lower LVEF and better outcomes is ex-
plained in part by arrest etiology. However, a similar
trend linking higher LVEF to poorer outcome was found
in subgroup analysis restricted to patients with ventricu-
lar arrhythmia.
Other baseline differences may exist between patients
that were not adequately measured or addressed in this
study. Yet typical measures of overall illness severity
(APACHE II score, SOFA score, number of organ fail-
ures) did not differ by normal vs low LVEF, and analyses
adjusted for potential baseline differences. LVEF was not
associated with initial vasopressor dose, excluding base-
line shock severity as a confounder. Still, cardiac func-
tion may be augmented by infusion of vasopressors that
have concomitant inotropic effects, including norepin-
ephrine [39], complicating attribution of shock subtype
by LVEF without ancillary supportive data.
Therapeutic hypothermia was more commonly used in
patients with LVEF ≤ 40% due to their higher incidence
of ventricular arrhythmia. Yet hypothermia was not as-
sociated with neurocognitive outcome or survival in this
cohort, and including hypothermia as a model covariate
did not change the conclusions. LVEF was not associated
with mean arterial pressure at baseline or through 48 h,
such that differences in cerebral perfusion pressure are
unlikely to explain this association.
The present study used LVEF to infer underlying
shock physiology. The timing of LVEF assessment was
restricted to within 1 day of arrest for main analyses to
ensure transient myocardial stunning was accurately
identified.
LVEF alone is an imperfect surrogate of cardiac out-
put, although the likelihood that severely depressed sys-
tolic function signifies cardiogenic pathophysiology is
high in the setting of post-arrest shock [1]. Future stud-
ies should incorporate repeated measures of cardiac
function, systemic vascular resistance, and inflammatory
markers to better delineate shock physiology.
Overlap in hemodynamic features and underlying biol-
ogy undoubtedly exists among PCAS shock subtypes,
but such is not unique to the post-arrest patient. Cardio-
genic shock from acute coronary syndrome can cause
concomitant systemic inflammation, which in turn may
exacerbate myocardial dysfunction and impair peripheral
vascular compensation [40–42]. In septic shock,
inflammation-induced myocardial depression, microcir-
culatory derangements, and autonomic dysfunction con-
tribute to cardiac dysfunction [43–45]. Other classic
shock subtypes—hypovolemic and obstructive shock—
could also occur post arrest depending on underlying
precipitant of arrest. Despite this overlap, discerning the
predominant shock physiology may help guide prognos-
tication and therapeutic decision-making. Still, causation
cannot be inferred from this cohort study. Clinical trials
will be required to delineate treatment implications,
including the role, if any, for early aggressive volume
resuscitation in PCAS shock subtypes.
Conclusions
Distributive-predominant (noncardiogenic) shock—as
reflected by higher LVEF—was associated with worse
neurocognitive outcome, prolonged organ failures, and
higher mortality among patients in PCAS shock. Greater
volume resuscitation in the first 6 h post arrest was asso-
ciated with more favorable neurocognitive outcome and
survival among patients with distributive but not cardio-
genic shock physiology. Future studies with repeated
measures of complementary hemodynamic parameters
are needed to independently validate the prognostic and
therapeutic value for subtyping PCAS shock.
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